Rate My Professor Kenia Nunes

As a vascular biologist, Nunes specializes in vascular dysfunction linked to diabetes, hypertension, and erectile dysfunction, focusing on the innate immune system's contributions through Toll-like receptor 4 (TLR4) and heat shock protein 70 (HSP70). Her Nunes Lab employs cell cultures, murine models, and human tissues to explore pharmacological targets, including two patents for spider toxin PnTx2-6 in erectile dysfunction treatment, developed with Brazilian and French collaborators. Key publications include 'Hypertension and erectile dysfunction: breaking down the challenges' (American Journal of Hypertension, 2021), 'New insights into RhoA/Rho-kinase signaling: a key regulator of vascular contraction' (Small GTPases, 2021), 'Blockade of the TLR4–MD2 complex lowers blood pressure and improves vascular function in a murine model of type 1 diabetes' (Scientific Reports, 2020), and 'Increased eHSP70-to-iHSP70 ratio disrupts vascular responses to calcium and activates the TLR4-MD2 complex in type 1 diabetes' (Life Sciences, 2022). Nunes has secured major funding, including a National Institutes of Health grant ($486,000, 2022–2025) for HSP70's dual role in diabetes-associated vascular dysfunction, American Heart Association grants totaling $370,000, and a Florida Space Research Program award ($50,000, 2018–2019). Her contributions advance therapeutic strategies for vascular diseases.